Sorrento Therapeutics Inc (SRNE)

[youssef]

From Endpoints website, which lists Adam F as an editor — they couldn’t hold this news back. “Sorrento Therapeutics’ oral Mpro inhibitor olgotrelvir has hit the primary endpoint and a key secondary endpoint in a Phase III trial that recruited adults with mild-to-moderate Covid. Subsequently, the company has reached out to China’s NMPA with an eye to submitting an NDA for expedited review. In the primary endpoint of median time to sustained recovery of 11 Covid symptoms, olgotrelvir reached 8.6 days compared with 11 days with placebo. It also reduced participants’ viral load compared with placebo.”